Site search
2831 results for '' found
Assessing the role of mepolizumab in DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome: a pilot study (ACTRN12621001333808)
Assessing the role of mepolizumab in DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome: a pilot study (ACTRN12621001333808)
/
DREAMM7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with t
DREAMM7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with t
/
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease: a randomised controlled trial - DISCUS-IBD (ACTRN12622001458729)
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease: a randomised controlled trial - DISCUS-IBD (ACTRN12622001458729)
/
Validation of the Discovery NM 530c, dedicated cardiac camera, for the measurement of left ventricular ejection fractions with gated cardiac blood-pool imaging using the current Alfred protocol (
Validation of the Discovery NM 530c, dedicated cardiac camera, for the measurement of left ventricular ejection fractions with gated cardiac blood-pool imaging using the current Alfred protocol (
/
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Availabl
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Availabl
/
A multi-centre, open-label innovation study in pancreatic cancer utilising Nanoknife® System for Irreversible Electroporation (IRE) in unresectable stage 3 pancreatic adenocarcinoma (ACTRN126210
A multi-centre, open-label innovation study in pancreatic cancer utilising Nanoknife® System for Irreversible Electroporation (IRE) in unresectable stage 3 pancreatic adenocarcinoma (ACTRN126210
/
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardio
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardio
/
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) (N
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) (N
/
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer [DeL
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer [DeL
/
Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect: Guided Physiologic Stenting (short title: DEFiNE GPS) (NCT04451044)
Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect: Guided Physiologic Stenting (short title: DEFiNE GPS) (NCT04451044)
/